secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001193125-22-211808
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q2 2022: PYRUKYND revenue $3.1M; net loss $91.8M; CEO transition to Brian Goff
--------------------------------------------------------------------------------

- Q2 2022 net loss from continuing ops $91.8M vs $82.8M Q2 2021; R&D expenses rose to $74.5M.
- PYRUKYND generated $3.1M net U.S. revenue in first full quarter after Feb 2022 FDA approval.
- Cash, equivalents, marketable securities $1.1B, down from $1.7B; expects to fund to cash-flow positivity.
- Brian Goff becomes CEO Aug 8; current CEO Jackie Fouse transitions to Chair of Board.
- Five pivotal PYRUKYND studies enrolling across thalassemia, sickle cell, pediatric PK deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522211808/0001193125-22-211808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522211808/d389470d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-211808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer